This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

Pioneering device to deliver 90 second heart screening

15 February 2017

Heart patients could be screened in just 90 seconds using a wireless, hand-held device now in development.

The RapidRhythm wireless handheld electrocardiogram (ECG) device

More than half a million people in the UK suffer from atrial fibrillation (AF), which causes an irregular heart rate, and identifies a high risk of stroke. AF results in 575,000 hospital admissions a year and more than 900,000 people live with the after effects of stroke.

The current method of screening is an electrocardiogram (ECG) test, for which patients undress and lie down to have ten electrodes connected to their body by a qualified medical professional. The procedure can take up to 20 minutes.

The RapidRhythm device is held to a patient’s chest to diagnose AF and other major cardiac conditions. Data is relayed to a LCD touchscreen displaying a high resolution, multichannel ECG trace and wirelessly downloaded for further analysis by a physician.

The latest version of RapidRhythm has been developed by product design specialist AME Group and electronics and software developer Practical Control.

The device conducts a full eight or 12-lead ECG measurement and can be used in a number of clinical settings. It gives the user high-definition video guidance on how to conduct the test, requires less training time for GPs, doctors and nurses than traditional ECG machines and can be used without the need for patients to undress. 

The RapidRhythm device can securely transfer the ECG recording to a remote interpretation service or nearby printer for on-site analysis.

AME’s designers have developed an ergonomic solution that enables a range of electrode types to be easily attached to the device and applied to the patient. Once the test has been completed the electrodes are removed at the touch of a button.

The RapidRhythm wireless handheld electrocardiogram (ECG) device

Patients have been involved throughout the user-focused design process. AME conducted on-site interviews at GP surgeries and heart wards to observe users and understand current ECG tests in order to find problems and opportunities for innovation.

The findings identified a number of unique product features that were explored across a range of design concepts. These include a single-handed electrode application process, automatic electrode release system, ergonomic form and obvious grip for left or right-handed use.

These designs were presented to patients and healthcare professionals to identify a preferred design.

The product was engineered in 3D CAD, with a number of test prototypes created using AME’s in-house facilities. AME’s low volume production facilities will be used to manufacture a small quantity of the devices, which will then be used to validate the product in the field.

Tim Stern, design manager at AME Group, said: “Observing and understanding the environment in which products are used can have a significant impact on the design output so we took time to fully understand users and patients and how they engaged with existing ECG products. 

“The findings were integral to how we explored and developed the aesthetics, features and ergonomics of the RapidRhythm device.

Prototyping is essential to the development process and enables our engineers to assess a design, highlight issues and minimise the risk and potential costs of resolving them at a later date.”

Sheffield-based AME Group has been at the forefront of new product development and 3D printing for almost 20 years, during which time it has designed, developed and prototyped products for brands including LG Harris, GlaxoSmithKline, Morphy Richards and Unilever.


Contact Details and Archive...

Print this page | E-mail this page